Immuron Limited (NASDAQ:IMRN) is one of the best performing ASX stocks in 2025, reporting a 49% growth in global revenue for fiscal year 2025. Sales of flagship product Travelan drove North American sales up by 76% to A$2 million and Australian sales up by 40% to AU$5.3 million.

The company’s net loss for FY2025 decreased by 24% to AU$5.25 million, with loss per share improving to A$0.023. Gross margins remained strong at 65.4%, cash reserves were at AU$2.83 million, and shareholders’ equity stood at AU$8 million. Immuron specializes in orally delivered targeted polyclonal antibodies for gastrointestinal and infectious diseases.

While Immuron (IMRN) shows potential, other AI stocks may offer greater upside with less risk. For an undervalued AI stock poised to benefit from tariffs and onshoring trends, consider exploring our report.

Read more at Yahoo Finance: Immuron (IMRN) Posts 49% FY2025 Revenue Growth on Travelan Sales